Antibody-drug conjugates on the marchOne of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal Share XAntibody-drug conjugates on the marchhttps://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/
The three biggest challenges in lung cancer, and how researchers are tackling themDespite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just Share XThe three biggest challenges in lung cancer, and how researchers are tackling themhttps://pharmaphorum.com/views-and-analysis/the-three-biggest-challenges-in-lung-cancer-and-how-researchers-are-tackling-them/
Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and BrexitMarc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for Share XSanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexithttps://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/
Pfizer and the UK cancer landscape: the pharmaphorum podcastPfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK Share XPfizer and the UK cancer landscape: the pharmaphorum podcast
Q&A: Avacta’s Amrik Basran on immunotherapyDr Amrik Basran from Avacta explains the current state of cancer immunotherapy and the challenges of moving into Share XQ&A: Avacta’s Amrik Basran on immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/avactas-amrik-basran-on-immunotherapy/
Demonstrating the value of RWEA new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional Share XDemonstrating the value of RWEhttps://pharmaphorum.com/views-analysis-oncology/demonstrating-the-value-of-rwe/
Q&A: Draper’s Jenna Balestrini on the future of CAR-TAs exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential. Jenna Share XQ&A: Draper’s Jenna Balestrini on the future of CAR-Thttps://pharmaphorum.com/views-analysis-oncology/qa-drapers-jenna-balestrini-on-the-future-of-car-t/
The state of personalised medicine in 2019Things are good, and they’re getting better. When researchers completed mapping the human genome in 2003, it broke Share XThe state of personalised medicine in 2019https://pharmaphorum.com/views-analysis-oncology/the-state-of-personalised-medicine-in-2019/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
